Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 21.
doi: 10.1007/s11897-024-00658-w. Online ahead of print.

Is There a Mitochondrial Protection via Remote Ischemic Conditioning in Settings of Anticancer Therapy Cardiotoxicity?

Affiliations
Review

Is There a Mitochondrial Protection via Remote Ischemic Conditioning in Settings of Anticancer Therapy Cardiotoxicity?

Petra Kleinbongard et al. Curr Heart Fail Rep. .

Abstract

Purpose of review: To provide an overview of (a) protective effects on mitochondria induced by remote ischemic conditioning (RIC) and (b) mitochondrial damage caused by anticancer therapy. We then discuss the available results of studies on mitochondrial protection via RIC in anticancer therapy-induced cardiotoxicity.

Recent findings: In three experimental studies in healthy mice and pigs, there was a RIC-mediated protection against anthracycline-induced cardiotoxicity and there was some evidence of improved mitochondrial function with RIC. The RIC-mediated protection was not confirmed in the two available studies in cancer patients. In adult cancer patients, RIC was associated with an adverse outcome. There are no data on mitochondrial function in cancer patients. Studies in tumor-bearing animals are needed to determine whether RIC does not interfere with the anticancer properties of the drugs and whether RIC actually improves mitochondrial function, ultimately resulting in improved cardiac function.

Keywords: Anthracycline; Cancer-treatment; Cardioprotection; Cardiotoxicity; Mitochondria; Remote ischemic conditioning.

PubMed Disclaimer

Similar articles

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Murphy E, Ardehali H, Balaban RS, DiLisa F, Dorn GW 2nd, Kitsis RN, et al. Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. Circ Res. 2016;118:1960–91. https://doi.org/10.1161/RES.0000000000000104 . - DOI - PubMed - PMC
    1. Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, Galluzzi L. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nat Rev Cardiol. 2019;16:33–55. https://doi.org/10.1038/s41569-018-0074-0 . - DOI - PubMed - PMC
    1. • Rocca C, Soda T, De Francesco EM, Fiorillo M, Moccia F, Viglietto G, et al. Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer. J Transl Med 2023;21:635. https://doi.org/10.1186/s12967-023-04498-5 . Very comprehensive recent review discussing the various effects of different anticancer agents on mitochondria and mitochondrial function.
    1. Harrington JS, Ryter SW, Plataki M, Price DR, Choi AMK. Mitochondria in health, disease, and ageing. Physiol Rev. 2023;103:2349–422. https://doi.org/10.1152/physrev.00058.2021 . - DOI - PubMed
    1. • Bikomeye JC, Terwoord JD, Santos JH, Beyer AM. Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol 2022;323:H702-H20. https://doi.org/10.1152/ajpheart.00231.2022 . Very comprehensive recent review discussing the various effects of different anticancer agents on mitochondria and mitochondrial function.

LinkOut - more resources